By continuously refining its practices through real-time feedback and innovative solutions, KFSHRC remains a leader in ...

Cullinan and Taiho have a broad development program for zipalertinib through a suite of REZILIENT studies, including two ongoing pivotal studies in 1L and 2L+ ex20ins NSCLC as well as studies in other ...

Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the ...

OrigAMI-1 is the first study to show amivantamab plus chemotherapy may provide clinically meaningful benefits to patients with metastatic colorectal cancer who have not received any EGFR-targeted ...

The presented posters “ Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations ” and “ ...

While the FDA will take into consideration the committee’s vote, the vote is not binding upon the agency. The FDA will make the final decision and has assigned a Prescription Drug User Fee Act (PDUFA) ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) has reiterated its commitment to ethical innovation in its efforts ...

RIYAD, Arabie saoudite, 13 sept. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSHRC) a ...

A webcast of the presentation will be available here beginning at 1:20 pm ET on Wednesday, September 18, 2024 and will be posted on the Investors section of the Company’s website. About Krystal ...

Virtual Ophthalmology Summit focused on age-related macular degeneration (AMD) and diabetes-related ocular diseases and featured 8 companies pursuing various differentiated approaches in treating ...

The Goldman Sachs symposium will feature a compelling agenda of fireside chats, panel discussions, founders, and industry leaders. Through these sessions, conference participants will explore emerging ...

About Seres Therapeutics Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company focused on improving patient outcomes in medically vulnerable populations through novel live ...